Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel HBV Biomarkers for Occult Infection in Liver Transplant
NCT04199819Unknown
- Sponsor
- The University of Hong Kong
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of entecavir in hepatitis B (HBV), sponsored by The University of Hong Kong. Primary endpoint: Proportion of HBsAg-negative recipients of an anti-HBc+ graft needing antiviral therapy at 2 years. Status: unknown.
02
Drugs
entecavir
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04199819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04199819.